University of Vermont
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Vermont sits in the top decile of US sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count).
University of Vermont: 162 sponsored US clinical trials, 15 recruiting.
University of Vermont sponsors 162 registered US clinical trials on ClinicalTrials.gov, 15 of them currently recruiting, and 132 completed. 5 of these trials are in Phase 3-4 (later-stage) and 49 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid-Related Disorders, with 4 trials.
Top-decile sponsor footprint
University of Vermont ranks in the top decile of sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
132 of 141 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
162 total, page 3 of 4
Platelet Reactivity After CABG
NCT01793597
Effects of Quitting Study A Test of Pre-clinical Findings
NCT01824511
EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial
NCT01853202
Treatment of Smoking Lapses and Relapses
NCT01807871
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
NCT01719302
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
NCT01488279
Study of the Effects of Education on Patients With Chronic Obstructive Pulmonary Disease
NCT01633697
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
NCT01524653
Detection of Celiac Disease in Patients With Hypothyroidism
NCT01862510
Changing the Paradigm of In-Hospital Cardiopulmonary Resuscitation
NCT01558817
Improving Effective Contraceptive Use Among Opioid-maintained Women
NCT01425060
Before-School Physical Activity Intervention in Elementary School Children
NCT01505244
Branched Chain Amino Acid Plus Glucose Supplement Reduces Exercise-Induced Delayed Onset Muscle Soreness in College Females
NCT01781910
Nasogastric Tube Insertion Using Midazolam in the Emergency Department
NCT01375634
Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis
NCT01252498
Internet Obesity Treatment Enhanced With Motivational Interviewing
NCT01232699
Chronic Muscle Disuse in the Elderly
NCT01190046
Attempts to Stop/Reduce Marijuana Among Dependent Users
NCT01039415
Saturated Fat Versus Monounsaturated Fat and Insulin Action
NCT01612234
Mechanisms of Specific Trunk Exercises in Low Back Pain
NCT01362049
Outcomes of Oncology Therapy in the Elderly: Trajectory of Functional Decline and Correlates of Change
NCT01006902
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
NCT01004393
Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors
NCT01482702
Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy
NCT00970905
The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins
NCT01341171
Using Functional MRI to Evaluate Cognitive Behavioral Therapy Treatment Response in Adults With Chronic Pain
NCT00796536
Natural History of Attempts to Stop Smoking
NCT00995644
Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)
NCT00787644
Cognitive-behavioral Therapy vs. Light Therapy for Preventing SAD Recurrence
NCT01714050
The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy
NCT00727948
Pioglitazone Incretin Study
NCT00656864
The Effect of Caffeine Reduction on Snoring and Quality of Life
NCT00641810
Treatment Trial for Post-Thrombotic Syndrome
NCT00633971
The Relationship of TV Viewing to Energy Balance in Adults
NCT00622050
Impaired Adipogenesis in Insulin Resistance: Pilot Clinical and In Vitro Studies
NCT00560469
The Effect of the Mini-pill on Blood Factors in Women at Increased Risk for Forming Blood Clots
NCT00580424
Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm
NCT00710255
The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease
NCT00498342
Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
NCT00416182
Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)
NCT00594087
Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma
NCT00486564
Evaluating the Relationship Between Blood Clotting Disorders, Inflammation, and Obesity in Individuals With Venous Disorders and Post-Thrombotic Syndrome
NCT00395265
Voucher Based Incentives to Treat Pregnant Smokers
NCT01801384
Internet Assisted Obesity Treatment
NCT00265954
Gradual vs. Abrupt Cessation Treatment for Smoking
NCT00297492
A Telephone Feedback System for Prevention of Chronic Pain Relapse
NCT00266773
Evaluation of an Outpatient Modified Prescription Form
NCT00256594
Using Telephone Technology to Prevent Relapse After Alcoholism Treatment
NCT00132795
Anxiety Sensitivity Program for Smoking Cessation
NCT00387049
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
NCT00619671
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 26 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Therapeutic Areas
What is open in the University of Vermont pipeline
15 recruiting of 162 indexed (9% open); 132 completed (81%).
Phase mix: 5 late (III/IV) vs 49 early (I/II) (early-phase heavy).
Top condition: Opioid-Related Disorders (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Vermont: open-pipeline peers nationwide
Peers matched on 162 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
University of Vermont sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 162 trials (± recruiting share)
- Alexion Pharmaceuticals · 162 trials · 10% recruiting
- Temple University · 163 trials · 13% recruiting
- Tufts University · 163 trials · 6% recruiting
- Wayne State University · 163 trials · 13% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- Eli Lilly and Company · 9% recruiting · 1,341 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this University of Vermont page
162 registered trials is a research-attention snapshot, not an endorsement of University of Vermont or any single study.
- 15 of University of Vermont's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid-Related Disorders is the condition University of Vermont studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid-Related Disorders trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Vermont pipeline card: 162 registered trials from official public datasets.Report a data error.